Vertex Pharmaceuticals Inc. presented new interim data at the American Society of Nephrology Kidney Week 2025 for its therapy povetacicept in IgA nephropathy and primary membranous nephropathy. The ongoing trial showed promising results for both conditions, with significant reductions in protein levels, stabilization of kidney function, and high rates of remission. The therapy was well tolerated with mostly mild or moderate side effects reported. These findings suggest povetacicept may be a potential treatment option for autoimmune kidney diseases. Further research is needed to fully understand its effectiveness and long-term safety.

Read more at Nasdaq: Vertex Unveils Positive 48-Week Data For Povetacicept In IgAN And PMN